Lloyds Banking Share Discussion Threads

[pal44] 09/1/2019 15:29

Polar add that Gove will switch to remain and be PM .. just watch :)

[utyinv] 09/1/2019 15:25

Polar,

I would imagine the stock to rise a little into the results. Yes the political issue is a distraction suppressing the price but if you look at the trend it tends to rally when there is more certainty and when there is uncertainty it is sold off. However, I guess this is just temporary and if we stay or leave the EU, stability will be restored in time and the share price should get back to where many analysts believe is a fair price ie 80p

[polar fox] 09/1/2019 15:17

On the detail, the share price reached a high of 54.50 a few minutes after the vote and folk have been taking some profit since, as per the chart above.

The low was 49.515 on Dec.28. Will that hold into the future?

[polar fox] 09/1/2019 14:59

Tom ND tweet:

The significance:
1. Practically, much harder for No10 to run down the clock to No Deal now
2. The battle of the amendment shows Bercow ready to break precedent to help MPs v HMG - and will do it again
3. So; Brexit will be softer
4. And a 2nd referendum made more likely

[xxxxxy] 09/1/2019 14:53

US and China. That is the question.


47 good. My view

[xxxxxy] 09/1/2019 14:51

In the background are bigger pictures.

And the EU remains sclerotic.



LEAVE and WTO

[polar fox] 09/1/2019 14:42

The amendment gives the gov't three days, if the MV is lost next week, to come back to Parliament with its proposals. Parliament may then amend things any way it likes. That will put Parliament in control of the process. What happens then, is anyone's guess.

Will she run away again from a vote next week? Dare she? The problem is she cannot be trusted in the slightest.

[xxxxxy] 09/1/2019 14:32

The greive thing will not do it. Legal. Awkward.

LEAVE and WTO

[philanderer] 09/1/2019 14:28

In it's 2019 banking sector outlook Barclays repeated “overweight” ratings on Lloyds and Royal Bank of Scotland based on “depressed valuations and potential for a constructive Brexit outcome”.

[xxxxxy] 09/1/2019 14:26

Share price more to do with usa snd china rather than brexit.

To be honest

[action] 09/1/2019 14:14

First target is 56p b4 result.

[polar fox] 09/1/2019 14:13

My concern is that the SP, from the wave pattern, may be at a S/T high. So the risk may be down i.e. vote fails, amendment lost. We'll see.

[polar fox] 09/1/2019 14:08

While we've been waiting for the vote, which now seems close, the share price has risen to 54.49, a high since Dec.7.

VOTE UNDERWAY.

[stonedyou] 09/1/2019 13:59

If there`s a general election remainer soubry will not be an MP....Hooorah!!




Use the 'nuclear option', ministers tell May: PM is urged to trigger an April 4 ELECTION to stop MPs blocking no-deal Brexit




•Theresa May facing another desperate battle against MPs to save her Brexit deal

•Tory and Labour Remainers mounting all-out bid to prevent a no-deal Brexit

•Some Conservatives threatening to back a no-confidence vote in government

•Mrs May being urged to dissolve Parliament for election in March if necessary


Theresa May is being urged to stop MPs blocking a no-deal Brexit by the 'nuclear option' of dissolving Parliament while it takes place.

[stonedyou] 09/1/2019 13:47

There you have it the "HATED EU" and the RICH hand in hand......



"In general, the current system of EU energy subsidies works very well for the rich."


Daniel Hannan


However, in his 2016 book "What next: How to get the best from Brexit”, Conservative MEP and Leave campaigner Daniel Hannan claimed the reason why “Britain has some of the highest electricity and gas bills in the world" in the first place is "because of EU policy”.


Mr Hannan wrote: “Brussels drives prices up in two ways: through setting renewables targets and, since 2010, through direct legislation.

“As a result, medium-sized business in the EU pay 20 per cent more for energy than an equivalent firm in China, 65 per cent more than one in India and 100 per cent more than one in the US.

“These artificially high energy prices have already closed most of Britain’s steel industry, and now threaten other high-energy manufacturers."

Mr Hannan went on to explain how the prices have also made an impact outside manufacturing, adding: "In 2012/2013, the NHS spent an extraordinary £630million on energy bills.”

The Conservative politician added that it is true the world is seeking to reduce carbon emissions and that Britain will presumably remain part of that global effort after Brexit.

However, Mr Hannan claimed the EU “does’t simply set a target for emissions cuts and leave it to the member states to meet it” as it would be to accept the “supremacy” of the approach agreed at the 2015 Paris Climate Change.

He concluded: “Instead, Brussels supports specific forms of alternative energy in a way which has the incidental effect of purchasing the loyalty of those who supply it.

"In general, the current system of EU energy subsidies works very well for the rich."

[bioking] 09/1/2019 13:32

OT) Please look at Futura Medical (FUM) has a dirt low market cap of 19 Million and has 3 Drugs including a potential MEGA Blockbuster in Phase 3 for the treatment of erectile dysfunction which works way faster than market leaders like Viarga and Cialis . If you look for a potential 10+ Bagger then load up FUM


Research Confirms MED2002's US$1 Billion Potential
hxxps://futuramedical.com/content/news/archive17/060317b.asp

The latest market research further endorses Futura's strategy of developing MED2002 as a prescription product in standard and increased strength dose forms, with the objective of switching the standard dose form to an OTC product at an appropriate time.

Ipsos's validated healthcare forecasting model was used to predict peak OTC annual sales for MED2002 in key countries worldwide in excess of US$650 million. This forecast follows earlier market research commissioned into the potential of MED2002 as a prescription product, which indicated a prescription market size of up to US$600 million in key countries worldwide.

Ipsos forecasts that 70% of OTC product sales will be incremental to the prescription ED category. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions is predicted to be more than US$1 billion prior to the expiry of the product's expected patent life.

The Ipsos valuation was based on the outcomes from primary market research carried out amongst 400 men with ED or suspected ED in the USA. The respondents were in four groups: satisfied users of PDE5 inhibitors (the class of drugs such as Viagra and Cialis); dissatisfied users of PDE5 inhibitors; diagnosed but untreated ED sufferers; and suspected though undiagnosed ED sufferers. The respondents were shown a concept about MED2002 as part of the market research though they did not use the product as it is currently in clinical development.

The key findings of the market research showed that the respondents believed that the product, once approved, is highly differentiated from existing products and that its claims would meet their needs. MED2002's rapid onset of action, an average of less than five minutes, was the key feature that attracted respondents to the product and could command a price premium compared with existing ED treatments, which have a substantially slower onset of action.

The Ipsos healthcare forecasting model has been demonstrated by Ipsos to be within 20% of actual sales volumes in 9 out of 10 of its forecasts.


Pipeline
hxxps://www.futuramedical.com/media/144144/Pipeline-2018.jpg

MED2002 (topical treatment for erectile dysfunction) hxxps://futuramedical.com/content/products/med_2002.asp

first patient dosed: in Q3/Q4 2018
Last patient dosed: by end of June 2019
Headline efficacy results: by end of December 2019

CSD500: Erectogenic condom
hxxps://futuramedical.com/content/products/csd_500.asp

Significant milestone achieved with approval of 2-year shelf life approved for CSD500, the erectogenic condom in September 2018. Development now complete. Discussions are ongoing with current and potential further distribution partners on next steps with the product in a number of markets.

Pain relief products: TPR100 (diclofenac) and TIB200 (ibuprofen) hxxps://futuramedical.com/content/products/tpr_100.asp

TPR100 commercial partner Thornton & Ross filed for UK regulatory submission in July 2018.
Out-licensing discussions for TPR100 outside of the UK are ongoing.

[polar fox] 09/1/2019 13:14

Thanks - Bercow busy batting away many points of order, before the vote atm. All on the telly 232.

[cannyshoveyergrannyoffthebus] 09/1/2019 13:11

just stop replying to stoned you .

[inaminute] 09/1/2019 13:07

I applaud your attempts to make this board relevant

[polar fox] 09/1/2019 13:04

The Grieve amendment is due to be voted on beginning shortly. Whips have summoned all MPs to vote. It's going to be close, according to Norman Smith. It needs to be passed for Parliament to have the potential to take control of the Brexit process next week, if the MV is lost, as most expect.

Meantime, LLOY has risen to a 1-month high - which says what the market is hoping.